EuroEyes International Eye Clinic Limited (1846) AI Stock Analysis

• Market Cap: HK$975.31M
• Dividend Yield: 1.99%
• Average Volume (3M): 156.72K
• Price to Earnings (P/E): 13.0
• Beta (1Y): 0.22
• Revenue Growth: -1.61%
• EPS Growth: -27.39%
• Country: HK
• Employees: 322
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.12
• Shares Outstanding: 320,706,000
• 10 Day Avg. Volume: 164,000
• 30 Day Avg. Volume: 156,720
• PEG Ratio: -0.42
• Price to Book (P/B): 1.19
• Price to Sales (P/S): 1.82
• P/FCF Ratio: 11.11
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 69 Neutral
• Price Target: HK$3.50 ▲(14.75% Upside)

The overall stock score reflects strong financial stability and reasonable valuation, offset by concerns about declining profit margins and missing cash flow data. Technical indicators suggest neutral market momentum, neither strongly positive nor negative.

Positive Factors

Financial Stability

A strong equity position with low leverage indicates financial stability, reducing financial risk and providing a solid foundation for future growth.

Revenue Growth

Consistent revenue growth reflects strong demand for services, indicating successful market expansion and product adoption over time.

Operational Management

Effective operational management is demonstrated by stable EBIT and EBITDA margins, ensuring profitability despite pressures on cost management.

Negative Factors

Profit Margin Decline

Declining profit margins suggest challenges in cost management, which could impact long-term profitability if not addressed.

Cash Flow Concerns

The absence of cash flow data for 2024 raises concerns about the company's ability to generate cash, potentially affecting operational and financial flexibility.

Equity Decline

A decline in equity could indicate underlying financial issues, which may affect the company's ability to invest in growth and maintain financial health.

EuroEyes International Eye Clinic Limited Business Overview & Revenue Model

Company Description

EuroEyes International Eye Clinic Limited (1846) is a leading provider of advanced eye care services, specializing in vision correction procedures such as laser eye surgery, cataract treatments, and other ophthalmological services. With a strong presence in multiple countries, the clinic focuses on delivering high-quality eye care through state-of-the-art technology and a team of experienced professionals committed to patient-centered care. EuroEyes aims to enhance the quality of life for its patients by improving their vision and overall eye health.

How the Company Makes Money

EuroEyes generates revenue primarily through the provision of surgical procedures, including LASIK, cataract surgery, and other corrective eye treatments. The company charges patients for these services, which typically include pre-operative consultations, the surgical procedure itself, and post-operative care. Key revenue streams also come from selling vision-related products, such as prescription glasses and contact lenses, as well as offering premium services that might include personalized patient care packages. Additionally, EuroEyes may engage in partnerships with insurance providers to facilitate patient access to their services, further enhancing their revenue potential. The company may also benefit from referrals and collaborations with other healthcare providers, which can lead to increased patient volume and service uptake.

EuroEyes International Eye Clinic Limited Financial Statement Overview

Summary

EuroEyes International Eye Clinic Limited shows strong revenue growth and low leverage, indicating financial stability. However, declining profit margins and missing cash flow data for 2024 raise concerns about cost management and cash generation capabilities.

Income Statement

The company shows a consistent revenue growth trajectory, with revenue increasing from HK$427.2M in 2019 to HK$715.7M in 2024, indicating strong demand for its services. The Gross Profit Margin has slightly decreased from 47.8% in 2023 to 40.1% in 2024, suggesting some pressure on cost management. The Net Profit Margin also decreased from 18.4% to 11.5%. Despite these declines, EBIT and EBITDA margins remained reasonably robust, reflecting effective operational management.

Balance Sheet

The company maintains a strong equity position with an Equity Ratio of roughly 68.3% in 2024, indicating financial stability. The Debt-to-Equity Ratio is relatively low at 0.29, suggesting low leverage and reduced financial risk. However, a slight decline in Stockholders' Equity from 2023 to 2024 could be a potential concern if it continues.

Cash Flow

The lack of reported Operating Cash Flow and Free Cash Flow in 2024 raises concerns about the company's cash generation capabilities. In prior years, there was positive Free Cash Flow, indicating previously healthy operations. The absence of cash flow data for 2024 could signal potential operational or financial challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	724.43M	715.68M	714.29M	610.29M	632.93M	473.82M
Gross Profit	295.40M	286.59M	335.52M	270.84M	312.55M	214.10M
EBITDA	149.21M	141.89M	292.10M	220.44M	278.80M	173.62M
Net Income	76.53M	82.28M	131.24M	89.47M	133.56M	65.58M
Balance Sheet
Total Assets	1.81B	1.60B	1.75B	1.54B	1.37B	1.31B
Cash, Cash Equivalents and Short-Term Investments	769.46M	653.23M	720.38M	779.57M	861.58M	761.89M
Total Debt	345.45M	319.29M	384.26M	290.41M	221.48M	239.55M
Total Liabilities	512.51M	473.72M	588.09M	497.95M	328.55M	324.57M
Stockholders Equity	1.26B	1.09B	1.13B	1.01B	1.01B	953.29M
Cash Flow
Free Cash Flow	131.44M	117.41M	102.30M	152.46M	228.71M	40.12M
Operating Cash Flow	196.36M	197.75M	191.85M	208.76M	273.26M	78.46M
Investing Cash Flow	-65.24M	-83.83M	-180.28M	-131.81M	-59.90M	-38.13M
Financing Cash Flow	-144.70M	-136.82M	-102.76M	-102.22M	-69.18M	-116.37M

EuroEyes International Eye Clinic Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1846, the sentiment is Negative. The current price of 3.05 is below the 20-day moving average (MA) of 3.15, below the 50-day MA of 3.19, and below the 200-day MA of 3.06, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 43.82 is Neutral, neither overbought nor oversold. The STOCH value of 46.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1846.

EuroEyes International Eye Clinic Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3689	71 Outperform	HK$652.07M	7.09	5.33%	9.14%	0.47%	50.46%
1846	69 Neutral	HK$975.31M	13.04	6.35%	1.99%	-1.61%	-27.39%
2219	68 Neutral	HK$1.93B	10.01	7.31%	9.29%	-3.19%	-20.30%
3869	56 Neutral	HK$827.78M	5.69	30.40%	―	2.30%	―
6639	52 Neutral	HK$1.03B	39.67	1.27%	―	-4.30%	13.83%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
3309	47 Neutral	HK$2.07B	-17.62	-6.41%	1.20%	2.05%	-285.88%

EuroEyes International Eye Clinic Limited Corporate Events

EuroEyes Reports Growth in Eye Surgeries for Q3 2025

EuroEyes International Eye Clinic Limited reported a 5.6% increase in the total number of eye surgeries for the third quarter of 2025 compared to the same period in 2024, driven by a rise in lens exchange surgeries and a recovery in laser surgery volume. This growth indicates a positive trend in patient demand, enhancing the company’s performance and providing stakeholders with more comprehensive insights into its operational success.